COM-902 is under clinical development by Compugen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how COM-902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COM-902 is under development for the treatment of multiple myeloma and solid tumors including head and neck squamous cell carcinoma, non-small cell lung cancer, metastatic colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer. It is administered intravenously. The drug candidate is a high affinity (femtomolar) monoclonal antibody which acts by targeting TIGIT/PVRIG. TIGIT is an immune checkpoint protein in the B7/CD28 family.
For a complete picture of COM-902’s drug-specific PTSR and LoA scores, buy the report here.